Distinguished in Chronic Inflammatory Demyelinating Polyneuropathy

Steve Vucic

Cnr Hawkesbury And Darcy Roads, 
Westmead, NSW, AU 
Distinguished in Chronic Inflammatory Demyelinating Polyneuropathy
Cnr Hawkesbury And Darcy Roads, 
Westmead, NSW, AU 
OverviewLocationsClinical Research

Overview

Steve Vucic practices in Westmead, Australia. Mr. Vucic is rated as a Distinguished expert by MediFind in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. His top areas of expertise are Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy, and Gastrostomy.

His clinical research consists of co-authoring 316 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles in the study of Chronic Inflammatory Demyelinating Polyneuropathy.

Gender
Male

Locations

Cnr Hawkesbury And Darcy Roads, Westmead, NSW 2145, Australia
Other Locations
94 Mallett St, Camperdown, NSW 2050, Australia
Hawkesbury Rd, Sydney, NSW 2145, Australia
Barker St, Randwick, NSW 2031, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2025
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project.
Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project.
Enrollment Status: Completed
Publish Date: August 22, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

316 Total Publications

Neck flexion weakness predicts respiratory dysfunction in amyotrophic lateral sclerosis.
Neck flexion weakness predicts respiratory dysfunction in amyotrophic lateral sclerosis.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: September 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vucic's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 34 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile